Antiplatelet drugs
Antiplatelet drugs are medicines that keep platelets, a type of blood cell, from clumping together to form a clot. MedlinePlus says they are mainly taken by people who have had a heart attack or stroke, and calls bleeding the most common side effect of blood thinners as a group. This is the class page: what each medicine has been shown to do sits on its own page.
Also called Antiplatelets · Platelet aggregation inhibitors
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH heading D010975, Platelet Aggregation Inhibitors, is an exact match; its scope note covers drugs or agents that impair any mechanism leading to platelet aggregation. The MedlinePlus blood thinners page names antiplatelets as one of two types of blood thinners and anticoagulants as the other. The page records no trial result and no dose. It rests on those two sources and does not list the member medicines, which sit on their own pages.
Trials at a glance
The figures count the 1 registry trial in this atlas that names this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | All statuses |
|---|---|---|
| Phase 4 | 1 | 1 |
| All phases | 1 | 1 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Class
- Mechanism
- Prevent platelets from clumping together to form a clot (MedlinePlus).
Claims and evidence
No claims are published for this drug yet.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Record details
- Record id
cardio:antiplatelet-drugs- Content hash
ac24a6270a6047b04e569b5ba31ad0e921a2488aab1d6e75048161a61c8952a5